What’s the current market cap for Twist Bioscience stock?

Twist Bioscience (TWST) has a market cap of $6.2bn as of June 29, 2026.

What is the P/E ratio for Twist Bioscience stock?

The price to earnings (P/E) ratio for Twist Bioscience (TWST) stock is 0 as of June 29, 2026.

Does Twist Bioscience stock pay dividends?

No, Twist Bioscience (TWST) stock does not pay dividends to its shareholders as of June 29, 2026.

When is the next Twist Bioscience dividend payment date?

Twist Bioscience (TWST) stock does not pay dividends to its shareholders.

What is the beta indicator for Twist Bioscience?

Twist Bioscience (TWST) has a beta rating of 2.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Twist Bioscience stock | $TWST Share Price

About Twist Bioscience

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Ticker

$TWST

Sector

Health

Primary listing

NASDAQ

Employees

979

Headquarters

South San Francisco, United States

Website

www.twistbioscience.com

Twist Bioscience Metrics

BasicAdvanced

$6.2bn

-

-$1.34

2.23

-

What the Analysts think about Twist Bioscience

Analyst ratings (Buy, Hold, Sell) for Twist Bioscience stock.

Bulls say / Bears say

Twist delivered record Q2 FY2026 revenue of $110.7 million, up 19% year-over-year and marking its 13th consecutive quarter of sequential growth, with gross margin expanding to 51.6% (Ex. 99.1 8-K)

Management raised full-year 2026 revenue guidance to $442 million–$447 million and reiterated the goal of adjusted EBITDA breakeven in Q4 FY2026, signaling confidence in near-term profitability (8-K Filing)

AI-driven demand for Twist’s platform drove DNA synthesis and protein solutions revenue growth of approximately 28% year-over-year in Q2, supported by its AWS Bio Discovery partnership (MarketBeat)

Q2 FY2026 GAAP net loss widened to $44.0 million, up from $39.3 million a year earlier, underscoring persistent unprofitability despite revenue growth (SEC 10-Q)

Cash and cash equivalents fell to $122.7 million as of March 31, 2026 from $183.0 million at the start of fiscal year, reflecting significant operating cash burn and raising funding concerns (SEC 10-Q)

Selling, general and administrative expenses rose 20% year-over-year to $76.1 million in Q2 FY2026 from $63.7 million, pressuring margins and delaying profitability improvements (SEC 10-Q)

Data summarised monthly by Lightyear AI. Last updated on 19 Jun 2026.

Twist Bioscience Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Twist Bioscience Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Twist Bioscience News

AllArticlesVideos

Ozempic Linked To Lower Risk Of Violence In New Study

Forbes·2 weeks ago

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Business Wire·2 months ago

These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results

Benzinga·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Twist Bioscience

Ticker

Employees

Twist Bioscience Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Twist Bioscience

Analyst Ratings

Bulls say / Bears say

Twist Bioscience Financial Performance

Income Statement

Twist Bioscience Earnings Performance

Earnings per share (EPS)

Twist Bioscience News

Ozempic Linked To Lower Risk Of Violence In New Study

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results

Buy $TWST

Lightyear

Legal

Work with us

Bulls say / Bears say

Twist Bioscience/$TWST

About Twist Bioscience

Ticker

Employees

Twist Bioscience Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Twist Bioscience

Analyst Ratings

Bulls say / Bears say

Twist Bioscience Financial Performance

Income Statement

Twist Bioscience Earnings Performance

Earnings per share (EPS)

Twist Bioscience News

Ozempic Linked To Lower Risk Of Violence In New Study

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results

What’s the current market cap for Twist Bioscience stock?

What is the P/E ratio for Twist Bioscience stock?

Does Twist Bioscience stock pay dividends?

When is the next Twist Bioscience dividend payment date?

What is the beta indicator for Twist Bioscience?

Bulls say / Bears say